Symphogen gains multimillion investment  

2006.01.12
Biotech company Symphogen has gained a DKK 155 m investment from existing investors and Takeda Research Investment, the corporate venture arm of Japan's Takeda Pharmaceutical Company

Biotech company Symphogen has gained a DKK 155 m (USD 25 m) investment from existing investors and Takeda Research Investment, the corporate venture arm of Japan's Takeda Pharmaceutical Company. The money will be used to conduct clinical trials of Symphogen's first product, anti-RhD for the treatment of idiopathic thrombocytopenic purpura (ITC), a bleeding disorder in which the blood does not clot as it should.

Graeme Martin, CEO and President of Takeda Research Investment comments: "Symhogen's cutting edge recombinant antibody technologies represent an industry breakthrough that will impact the future of antibody therapeutics in multiple disease areas including infectious diseases and cancer".

Symphogen pioneers therapeutic products based on recombinant natural human antibodies for the treatment and prevention of human disease. Symphobodies offer a number of advantages over current plasma-derived immunoglobulins and monoclonal antibody therapies for the treatment of infectious diseases, allergy, transplant rejection, and cancer. The commercial potential of symphobodies is expected to be very significant. The news was reported by financial daily newspaper Børsen and on the Symphogen website.

Link > Symphogen 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×